Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

SAN DIEGO--(BUSINESS WIRE)---- $DHR #Covid19--Danaher Corporation (DHR) Misled Investors Regarding Revenue Growth Associated with the Company's COVID-19-related Businesses.

Danaher Corporation (DHR) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Danaher Corporation Securities Class Action

NEW YORK , July 21, 2023 /PRNewswire/ -- Bernstein Liebhard LLP: Do you, or did you, own shares of Danaher Corporation (NYSE: DHR)? Did you purchase your shares between April 21, 2022 and April 24, 2023, inclusive?

DANAHER CORPORATION SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Danaher Corporation (NYSE: DHR)

NEW YORK , July 20, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Danaher Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DHR

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

INVESTOR DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $DHR #Covid19--Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Danaher Corporation (NYSE: DHR) securities between April 21, 2022 and April 24, 2023. Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is this Cas.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Danaher Corporation (DHR)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2023. SO WHAT: If you purchased Danaher securities during the Class Per.

ROSEN, A LEADING NATIONAL FIRM, Encourages Danaher Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – DHR

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR), and certain officers. The class action, filed in the United States District Court for the District of Columbia, and docketed under 23-cv-02055, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Danaher securities between April 21, 2022, and April 24, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Danaher Corporation and Certain Officers - DHR

Lower demand for COVID-19 testing, vaccine and therapeutics is expected to have hurt Danaher's (DHR) Q2 performance. Rising cost of sales might have hurt the bottom line.

Will Low COVID-Testing Volumes Mar Danaher's (DHR) Q2 Earnings?

Collaboration Builds upon Fujirebio Expertise in Neurodegenerative Disease Assays and Beckman Coulter's High Sensitivity, High Throughput, Global Installed Base of Access Family of Immunoassay Analyzers BREA, Calif. and TOKYO , July 17, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test

ConocoPhillips

Schlumberger

The S&P 500 has advanced more than 20% from its bear market low. Some fear that the rally, led by megacap stocks, may be fragile.

Billionaire Ken Fisher Says Today's "Doom and Gloom" Is a Bullish Sign. Here Are the Stocks He's Betting On.

Becton, Dickinson and Co.

General Dynamics

General Motors

Goldman Sachs

Roper Technologies

Wells Fargo

Looking for undervalued blue-chip stocks to buy? This is a great time to be doing so.

The 7 Most Undervalued Blue-Chip Stocks to Buy Now: June 2023

Lower demand for COVID-19 testing, vaccine and therapeutics within the Biotechnology and Diagnostics segments weigh on Danaher (DHR).

Danaher (DHR) Shares Decline 10% YTD: What's Pulling It Down?

Despite a great history of beating the number, this stock is a Zacks Rank #5 (Strong Sell) as earnings estimates have fallen.

Bear Of The Day: Danaher (DHR)

The bioprocessing market is currently in a downturn and pulling companies like Danaher and Sartorius down. Danaher has a clean balance sheet to make good deals in this downturn. Margins have temporary headwinds but should recover in 2024.

Danaher: Poised To Thrive Amidst The Bioprocessing Downturn

Danaher's bioprocessing business faces short-term challenges in 2023, but the company remains a strong investment opportunity in the Medtech sector. The company's razor-blade business model, leading positions in attractive end markets, and strong organic growth combined with M&A make it a compelling investment. Despite short-term headwinds, Danaher is expected to achieve normalized high-single-digit organic sales growth and maintain a high operating margin after the spin-off of Environmental & Applied Solutions.

Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump

WASHINGTON , June 20, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2023 on Tuesday, July 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Danaher Schedules Second Quarter 2023 Earnings Conference Call

Caterpillar

The Bill and Melinda Gates Foundation Trust holds a small number of stocks in a highly focused portfolio. Caterpillar looks like a good buy for income-seeking investors.

Inside the Bill and Melinda Gates Foundation Trust: Unveiling 2 Great Stock Holdings

AbbVie

CME Group

Canadian Pacific Kansas City Limited

Carlisle Companies

Chevron

Deere & Company

Duke Energy

Extra Space Storage

Huntington Bancshares

Home Depot

L3Harris

Lockheed Martin

Nasdaq

Northrop Grumman

Norfolk Southern

PepsiCo

Public Storage

Pioneer Natural Resources

Raytheon Technologies

Union Pacific

Vanguard Dividend Appreciation ETF

Valero Energy

Exxon Mobil

My dividend growth portfolio consists of 22 individual stocks in eight sectors, with a focus on industries with high entry barriers and dominant positions in supply chains. The portfolio has delivered solid returns, outperforming the S&P 500 by 400 basis points annually since 2013, despite recent market challenges. Going forward, I plan on adding to cyclical holdings and expanding my real estate exposure while maintaining my long-term investment strategy.

My Improved Six-Figure Market-Beating Dividend Growth Portfolio

LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

Apple

American Express

Bank of America

Kraft Heinz

Coca-Cola

Schwab US Dividend Equity ETF

This year, so far, dividend investors are dealing with underperformance as the market has shifted from value to growth stocks. This is amplified by economic growth fears. While underperformance isn't fun, weakness comes with opportunities, which is why I have aggressively added to a number of Buffett-style dividend growth stocks.

Buy-Alert: 3 Undervalued Buffett-Style Dividend Gems I'm Buying

Thanks to its business model, Danaher has managed to reach operational excellence. Solid tailwinds will back up the company to continue its compounding path.

Danaher: A Great Chance To Buy This Long-Term Compounder

Catalent

Vornado Realty Trust

Wynn Resorts

Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There's also one falling Pharma company that (once again) delayed its Q3 results.

The Great Dividend Divide: Spotting Clues From 2 Telling Companies' Payout Changes

DxI 9000 Access Immunoassay Analyzer Boasts Industry's Highest Throughput per Footprint: Up To 215 Tests/Hour/Square Meter Innovations Bolster Assay Performance and Laboratory Productivity with New Analyte Processing and Detection Technology, Precision Sensors, Smart Algorithms, Remote Real-Time System Monitoring, and is the Only Immunoassay Analyzer with No Daily Maintenance i NT-proBNP Assay Now Available with Age-Based Cutoffs and Comorbidity Data ROME , May 15, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).

News for Danaher Stock (DHR)